Predicting response to CGRP(-receptor) monoclonal antibodies – learnings from super- and non-responders

  • In a retrospective cohort study, patients with migraine (n=260) were treated with preventative CGRP(-receptor) monoclonal antibodies. 11% and 10% were identified as super responders and non-responders respectively.
  • Those identified as super responders presented with more typical migraine characteristics such as vomiting, unilateral localization, pulsating character, photophobia, and nausea. Super responders responded better to triptans than non-responders (P=0.01).
  • The authors concluded that there are several clinical parameters that differ between individuals who are CGRP(-receptor) monoclonal antibody non-responders and super responders. Evaluation of clinical presentation prior to treatment might help in predicting likelihood of treatment success.